Prelude Therapeutics reported a net margin of -270.93% for the quarter ended Jun 2026. These financial ratios cover 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||||||
| EBT Margin | -1,145.87% | -845.78% | -314.12% | -307.59% | -309.54% | -270.93% | ||||||||||||||||||
| EBIT Margin | -1,145.87% | -845.78% | -314.12% | -307.59% | -309.54% | -270.93% | ||||||||||||||||||
| EBITDA Margin | -1,145.87% | -845.78% | -314.12% | -307.59% | -309.54% | -270.93% | ||||||||||||||||||
| Operating Margin | -1,145.87% | -845.78% | -314.12% | -307.59% | -309.54% | -270.93% | ||||||||||||||||||
| Net Margin | -1,145.87% | -845.78% | -314.12% | -307.59% | -309.54% | -270.93% | ||||||||||||||||||
| FCF Margin | -911.97% | -519.93% | -294.08% | 409.91% | -473.47% | -273.53% | ||||||||||||||||||
| Efficiency | ||||||||||||||||||||||||
| Assets AverageAssets Avg. | 340.40M | 318.16M | 292.88M | 269.86M | 250.69M | 231.41M | 209.41M | 239.47M | 269.56M | 268.09M | 262.39M | 235.70M | 210.76M | 186.37M | 158.39M | 128.09M | 104.84M | 118.03M | 130.48M | 154.50M | ||||
| Asset Utilization RatioAsset Util. | 0.05 | 0.10 | 0.10 | 0.13 | 0.15 | |||||||||||||||||||
| Valuation | ||||||||||||||||||||||||
| Price to EarningsP/E | -47.85 | -17.96 | -10.87 | -8.48 | -10.40 | -8.67 | -9.39 | -7.61 | -5.07 | -6.27 | -10.45 | -7.77 | -4.57 | -2.86 | -1.69 | -1.91 | -4.43 | -10.53 | -19.21 | -27.52 | ||||
| Price to SalesP/S | 52.34 | 24.16 | 13.93 | 32.39 | 59.47 | 74.57 | ||||||||||||||||||
| Price to BookP/B | 4.74 | 2.07 | 1.26 | 1.04 | 1.46 | 1.48 | 1.56 | 0.94 | 0.71 | 0.99 | 1.70 | 1.58 | 1.00 | 0.74 | 0.57 | 0.81 | 1.55 | 2.66 | 4.53 | 3.18 | ||||
| Enterprise Value | 1,154.61M | 297.74M | 58.87M | -0.66M | 88.27M | 83.62M | 97.04M | -12.39M | -65.14M | -2.47M | 153.02M | 104.77M | -0.65M | -41.01M | -44.76M | -15.75M | 24.90M | 76.26M | 127.79M | 144.72M | ||||
| EV to EBIT | -37.44 | -9.02 | -1.94 | 0.02 | -2.90 | -2.50 | -3.33 | 0.38 | 1.95 | 0.07 | -4.46 | -2.82 | 0.02 | 1.21 | 1.29 | 0.49 | -1.22 | -4.40 | -9.01 | -9.36 | ||||
| EV to EBITDA | -37.44 | -9.02 | -1.94 | 0.02 | -2.90 | -2.50 | -3.33 | 0.38 | 1.95 | 0.07 | -4.46 | -2.82 | 0.02 | 1.21 | 1.29 | 0.49 | -1.22 | -4.40 | -9.01 | -9.36 | ||||
| Market Capitalization | 1,475.48M | 593.02M | 329.10M | 249.69M | 316.35M | 289.39M | 273.34M | 246.64M | 169.41M | 234.51M | 358.99M | 288.65M | 157.02M | 96.65M | 58.36M | 61.51M | 90.53M | 182.71M | 272.39M | 425.35M | ||||
| Price to FCFP/FCF | -65.77 | -22.81 | -14.40 | -12.99 | -14.81 | -12.41 | -8.83 | -8.61 | -6.45 | -9.49 | -11.19 | -12.33 | -5.74 | -4.65 | -1.70 | -2.36 | -4.74 | 7.90 | -12.56 | -27.26 | ||||
| EV to FCF | -51.47 | -11.45 | -2.58 | 0.03 | -4.13 | -3.59 | -3.14 | 0.43 | 2.48 | 0.10 | -4.77 | -4.47 | 0.02 | 1.97 | 1.31 | 0.60 | -1.30 | 3.30 | -5.89 | -9.28 | ||||
| EV to CFO | -53.03 | -11.58 | -2.69 | 0.04 | -4.32 | -3.65 | -3.22 | 0.45 | 2.54 | 0.10 | -4.81 | -4.54 | 0.02 | 1.98 | 1.31 | 0.60 | -1.30 | 3.30 | -5.89 | -9.29 | ||||
| Return Ratios | ||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -1,145.87% | -845.78% | -1,928.67% | -314.12% | -307.59% | -309.54% | -270.93% | |||||||||||||||||
| Return on Capital Employed [ROCE]ROCE | -31.23% | -38.04% | -44.09% | -48.65% | -53.75% | -58.91% | -64.49% | -55.87% | -50.77% | -53.71% | -56.18% | -66.99% | -75.99% | -86.93% | -100.99% | -125.96% | -139.70% | -160.77% | -94.79% | -57.87% | ||||
| Return on Assets [ROA]ROA | -29.43% | -35.75% | -41.67% | -45.80% | -49.13% | -53.38% | -58.43% | -52.33% | -47.59% | -49.34% | -52.41% | -60.36% | -67.98% | -74.97% | -88.38% | -105.40% | -115.46% | -88.59% | -64.48% | -43.62% |